Physical Medicine and Rehabilitation Department - Pitié-Salpêtrière Hospital
Paris, 75013, France
NCT Number: NCT05977270
The goal of this clinical trial is to evaluate the effects of Lifebloom One in people who have suffered a stroke or a traumatic brain injury.
The main questions to be answered are:
* Does Lifebloom One allow users to spend more time standing each day? * Does Lifebloom One allow users to improve their balance and gait?
Participants will use Lifebloom One during 8 weeks.
For each participant, gait and balance are compared either with and without Oxilio or before and after Lifebloom One intervention.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Paris, 75013, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
LBO is made of Oxilio, an alternative to wheelchair placement for everyday use.
Time frame: Change from baseline to intervention phase
Time frame: Change from baseline to intervention phase
Time frame: Change from baseline to intervention phase
6-point scale. A score of 0 indicates that the patient is a non-functional ambulator, a score of 1, 2 or 3 denotes a dependent ambulator who requires assistance from another person in the form of continuous manual contact (1), continuous or intermittent manual contact (2), or verbal supervision/guarding (3) and a score of 4 or 5 describes an independent ambulator who can walk freely on: level surfaces only (4) or any surface (5=maximum score).
Time frame: Change from baseline to intervention phase
In this 14-item scale, patients must maintain positions and complete moving tasks of varying difficulty. In most items, patients must maintain a given position for a specified time. Patients receive a score from 0-4 on their ability to meet these balance dimensions. A global score can be calculated out of 56. A score of 0 represents an inability to complete the item, and a score of 56 represents the ability to independently complete the item.
Time frame: Change from baseline to intervention phase
A 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity according to a self-report scale. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.
Time frame: From the beginning and until the end of the intervention phase (during 8 weeks, one time per week)
Time frame: Before baseline, twice during the intervention phase, at immediate post-intervention
The score of the BI is a summed aggregate and there is preferential weighting on mobility and continence. The scores are allotted in the following way: 0 or 5 points per item for bathing and grooming; 0, 5, or 10 points per item for feeding, dressing, bowel control, bladder control, toilet use, and stairs; 0, 5, 10, or 15 points per item for transfers and mobility. The Index yields a total score out of 100 - the higher the score, the greater the degree of functional independence.
Time frame: Before baseline, at immediate post-intervention
It is a self-report scale containing 49 items. Items are rated on a 5-point Likert scale. Higher scores indicate better functioning.
Time frame: Before baseline, at immediate post-intervention
The PHQ-9 contains the 9 items. Each item is evaluated on a severity scale ranging from 0 to 3 where the respondent is asked to rate how often each symptom occurred over the last 2 weeks (0-not at all; 1-several days; 2-more than half of the days or 3-nearly every day), yielding a total score ranging from 0-27. Score interpretation:1-4 minimal depression; 5-9 mild depression; 10-14 moderate depression; 15-19 moderately severe depression; and 20-27 severe depression.
Time frame: at immediate post-intervention
Time frame: at immediate post-intervention
Lifebloom
Industry
Evaluation of the Effects of Lifebloom One on Physical Activity After Acquired Brain Injury: A Single-Case Experimental Study
Acronym: LBO_LCA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04930822
Acquired Brain Injury, Blindness
Wallingford, Connecticut, United States
View Trial DetailsNCT06945835
Behavior, Brain Damage, Chronic
West Hartford, Connecticut, United States
View Trial DetailsNCT03797378
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Birmingham, Alabama, United States
View Trial DetailsNCT03818204
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Boston, Massachusetts, United States
View Trial Details